2026 is highlighted as the year of the singularity with Elon Musk warning of underestimated impacts; conversations with him ...
Insilico now has a pipeline of more than 40 AI-developed drugs it is developing for conditions such as cancer, bowel and kidney disease.
Engineers at the University of California have developed a new data structure and compression technique that enables the ...
Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
The world’s most powerful supercomputers can now run simulations of billions of neurons, and researchers hope such models ...
CloseMate today opened early access for the world's first Fully Autonomous CRM powered by AGI-grade logic, introducing a ...
A University of Utah research team's rare find in a storage closet is being called a huge, historically significant discovery ...
AI coding tools are rapidly changing how we produce software, and the industry is embracing it—perhaps at the expense of entry-level coding jobs.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...
For almost a century, Science News journalists have covered advances in science, medicine and technology for the general public, including the 1925 Scopes “monkey” trial, the advent of the atomic age ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback